Crews, Craig M.

Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance

Salami, J., Alabi, S., Willard, R. R., Vitale, N. J., Wang, J., Dong, H., Jin, M., McDonnell, D. P., Crew, A. P., Neklesa, T. K., et al. (2018) · Communications Biology

Protein Degradation and InhibitorsProstate Cancer Treatment and Research

Cited by 349

MDM2-Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53

Hines, J., Lartigue, S., Dong, H., Qian, Y., & Crews, C. M. (2019) · Cancer Research

Protein Degradation and InhibitorsCancer-related Molecular Pathways

Cited by 348

Crystal Structure of Epoxomicin:20S Proteasome Reveals a Molecular Basis for Selectivity of α‘,β‘-Epoxyketone Proteasome Inhibitors

Groll, M., Kim, K. B., Kairies, N., Huber, R., & Crews, C. M. (2000) · Journal of the American Chemical Society

Ubiquitin and proteasome pathwaysEnzyme Structure and Function

Cited by 304

Small‐Molecule Inhibitors of the Interaction between the E3 Ligase VHL and HIF1α

Buckley, D. L., Gustafson, J. L., Van Molle, I., Roth, A. G., Tae, H. S., Gareiss, P. C., Jorgensen, W. L., Ciulli, A., & Crews, C. M. (2012) · Angewandte Chemie International Edition

Cancer, Hypoxia, and MetabolismHeterocyclic Compound Synthesis and Bioactivity

Cited by 302

Addressing Kinase-Independent Functions of Fak via PROTAC-Mediated Degradation

Cromm, P. M., Samarasinghe, K. T. G., Hines, J., & Crews, C. M. (2018) · Journal of the American Chemical Society

Protein Degradation and InhibitorsChemical Synthesis and Analysis

Cited by 293

Waste disposal—An attractive strategy for cancer therapy

Salami, J., & Crews, C. M. (2017) · Science

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 279

Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1

Crew, A. P., Raina, K., Dong, H., Qian, Y., Wang, J., Vigil, D., Serebrenik, Y. V., Hamman, B. D., Morgan, A., Ferraro, C., et al. (2018) · Journal of Medicinal Chemistry

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 257

Recent Developments in PROTAC‐Mediated Protein Degradation: From Bench to Clinic

Hu, Z., & Crews, C. M. (2022) · ChemBioChem

Protein Degradation and InhibitorsChemical Synthesis and Analysis

Cited by 231

Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation

Burslem, G. M., Schultz, A. R., Bondeson, D. P., Eide, C. A., Savage Stevens, S. L., Druker, B. J., & Crews, C. M. (2019) · Cancer Research

Protein Degradation and InhibitorsChronic Myeloid Leukemia Treatments

Cited by 212

Targeted Protein Degradation by Small Molecules

Bondeson, D. P., & Crews, C. M. (2017) · Annual Review of Pharmacology and Toxicology

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 207

Small‐Molecule‐Mediated Degradation of the Androgen Receptor through Hydrophobic Tagging

Gustafson, J. L., Neklesa, T. K., Cox, C. S., Roth, A. G., Buckley, D. L., Tae, H. S., Sundberg, T. B., Stagg, D. B., Hines, J., McDonnell, D. P., et al. (2015) · Angewandte Chemie International Edition

Protein Degradation and InhibitorsProstate Cancer Treatment and Research

Cited by 206

Pharmacological targeting of the pseudokinase Her3

Xie, T., Lim, S. M., Westover, K. D., Dodge, M. E., Ercan, D., Ficarro, S. B., Udayakumar, D., Gurbani, D., Tae, H. S., Riddle, S. M., et al. (2014) · Nature Chemical Biology

HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations

Cited by 205

Targeted degradation of transcription factors by TRAFTACs: TRAnscription Factor TArgeting Chimeras

Samarasinghe, K. T. G., Jaime-Figueroa, S., Burgess, M., Nalawansha, D. A., Dai, K., Hu, Z., Bebenek, A., Holley, S. A., & Crews, C. M. (2021) · Cell Chemical Biology

Protein Degradation and InhibitorsCRISPR and Genetic Engineering

Cited by 182

Enhancing Antiproliferative Activity and Selectivity of a FLT-3 Inhibitor by Proteolysis Targeting Chimera Conversion

Burslem, G. M., Song, J., Chen, X., Hines, J., & Crews, C. M. (2018) · Journal of the American Chemical Society

Protein Degradation and InhibitorsAcute Myeloid Leukemia Research

Cited by 176

Assessing Different E3 Ligases for Small Molecule Induced Protein Ubiquitination and Degradation

Ottis, P., Toure, M., Cromm, P. M., Ko, E., Gustafson, J. L., & Crews, C. M. (2017) · ACS Chemical Biology

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 176

Mutant-selective degradation by BRAF-targeting PROTACs

Alabi, S., Jaime-Figueroa, S., Yao, Z., Gao, Y., Hines, J., Samarasinghe, K. T. G., Vogt, L., Rosen, N., & Crews, C. M. (2021) · Nature Communications

Protein Degradation and InhibitorsMelanoma and MAPK Pathways

Cited by 152

Targeting the Undruggable Proteome: The Small Molecules of My Dreams

Crews, C. M. (2010) · Chemistry & Biology

Chemical Synthesis and AnalysisComputational Drug Discovery Methods

Cited by 147

The Proteasome in Modern Drug Discovery: Second Life of a Highly Valuable Drug Target

Cromm, P. M., & Crews, C. M. (2017) · ACS Central Science

Ubiquitin and proteasome pathwaysProtein Degradation and Inhibitors

Cited by 136

Modulation of Phosphoprotein Activity by Phosphorylation Targeting Chimeras (PhosTACs)

Chen, P.-H., Hu, Z., An, E., Okeke, I., Zheng, S., Luo, X., Gong, A., Jaime-Figueroa, S., & Crews, C. M. (2021) · ACS Chemical Biology

Protein Degradation and InhibitorsProtein Tyrosine Phosphatases

Cited by 130

Abstract 44: The discovery of ARV-471, an orally bioavailable estrogen receptor degrading PROTAC for the treatment of patients with breast cancer

Snyder, L. B., Flanagan, J. J., Qian, Y., Gough, S. M., Andreoli, M., Bookbinder, M., Cadelina, G., Bradley, J., Rousseau, E., Chandler, J., et al. (2021) · Cancer Research

Protein Degradation and InhibitorsEstrogen and related hormone effects

Cited by 126

Targeted Dephosphorylation of Tau by Phosphorylation Targeting Chimeras (PhosTACs) as a Therapeutic Modality

Hu, Z., Chen, P.-H., Li, W., Douglas, T., Hines, J., Liu, Y., & Crews, C. M. (2023) · Journal of the American Chemical Society

Alzheimer's disease research and treatmentsCholinesterase and Neurodegenerative Diseases

Cited by 98

Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties

Jaime-Figueroa, S., Buhimschi, A. D., Toure, M., Hines, J., & Crews, C. M. (2020) · Bioorganic & Medicinal Chemistry Letters

Protein Degradation and InhibitorsChemical Synthesis and Analysis

Cited by 88

Niedermolekulare PROTACs: neue Wege zum Abbau von Proteinen

Toure, M., & Crews, C. M. (2016) · Angewandte Chemie

Protein Degradation and InhibitorsChemical Synthesis and Analysis

Cited by 40